DOCSLIB.ORG

Action of Dilazep Dihydrochloride on Chemiluminescence from a Xanthine Oxidase/Acetaldehyde System

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Action of Dilazep Dihydrochloride on Chemiluminescence from a Xanthine Oxidase/Acetaldehyde System Jpn J ClinChem 19:350―353,1990. "A rticle" Action of Dilazep Dihydrochloride on Chemiluminescence from a Xanthine Oxidase/Acetaldehyde System Yasunobu Yoshinaka*, Toru Yokoyama* and Masaki Nakamura* *Tokyo Research Laboratories , Kowa Co., Ltd., 2-17-43 Noguchi-cho, Higashimurayama-city, Tokyo 189, Japan Received on Apr. 12, 1990, Accepted on Aug. 17, 1990 Key words: dilazep, chemiluminescence,xanthine oxidase, radical scavenger Summary Superoxide dismutase ISOD), catalase, hydroxyl radical (OH) scavengers and singlet oxygen (102) quenchers suppress the light signal from a xanthine oxidase/acetaldehyde system. Xanthine oxidase inhibitor allopurinol also suppresses the light signal from the system. Dilazep HCI (10-5-10-3M) suppresses the chemiluminescence in a concentration dependent manner without affecting the xanthine oxidase activity.These results suggest that dilazep exhibits a radical scavenger-like action. damage8).In this study,we determined the radi- Introduction cal scavenging effect of dilazep using chemilu- minescence from a xanthine oxidase/acet- Tetrahydro-1H-1,4-diazepine-1,4(5H)-dipro- aldehyde system. panol bis(3,4,5-trimethoxybenzoate) dihydroch- loride monohydrate (dilazep) has been success- Materials and Method fully employed in the treatment of patients with ischemic heart diseases and sequelae of cerebral The sources of materials used were as fol- vascular diseases.It exhibits unique pharmaco- lows:xanthine oxidase (grade ifi from butter logical effects,such as adenosine potentiation1,2), milk),superoxide dismutase(SOD from bovine platelet aggregation inhibition3),membrane stabi- erythrocytes)and catalase(from bovine liver) lization4) and improvement of red blood cell from Sigma,ethylenediaminetetraacetic acid dis- deformability5).Recent evidence indicates that odium salt (EDTA),1,4-diazabicyclo-(2,2,2)- dilazep prevents brain injury and brain lipid octane(DABCO),dimethylsulfoxide (DMSO) and peroxidation induced by reperfusion in rate and mannitol from Wako Pure Chemicals,dilazep decrement in cerebral blood flow caused by re- and sodium allopurinol from Kowa,sodium azide perfusion in dogs7) although the mechanism(s) is and benzoic acid from Showa Chemicals,acet- unclarified.Recently,oxygen radicals have been aldehyde from Merck,ethanol from Katayama suggested as mediators of ischemic brain Chemicals and methionine from Daiichi Chemi- 350 Fig.2.Dose-response curves of inhibition of drugs on chemiluminescence in a xanthine oxidase/ aeetaldehyde system Catalase(○);SOD(●);allopurinol(△); dilazep(▲);DMSO(□). Conditions are as in Fig.1. was started by the addition of 0.05ml of 1M .acetaldehyde to the reaction mixture,and the photon count was recorded for 7min.A net che- miluminescence value was calculated by the fol- Fig.1.Dilazep inhibition of the xanthine oxidase/ lowing equation: aeetaldehyde reaction Acetaldehyde(10mM)was added at zero time. Net chemiluminescence=Recorded count•| The xanthine oxidase concentration was 50 Background count mU/ml.Dilazep was added prior to acetal- The inhibition ratio of each tested substance dehyde addition. was determined at the peak time of the control Control(○― ○);10-6Mdilazep(● ― ●) reaction. 10.5Mdilazep(△― △);10-4M dilazep(▲― Xanthine oxidase activity with 1mM xanthine ▲);10-3Mdilazep(□― □). The sereactions were carried out in 5ml of as the substrate was assayed at 37•Ž by 0.05M potassium phospｈate,10-4M EDTA, measuring the absorption of uric acid at 292nm. pH7.8,30℃. Duplicate assays were performed for each experiment,and the result was expressed as the mean. cals. Chemiluminescence was measured by a chem- Results iluminescence analyzer(OX-7,Tohoku Electro- nics,Co.,Ltd.).One minute readings were made The time course of the xanthine oxidase/ for all experiments at 30•Ž.Five milliliters of aldehyde reaction and the effect of dilazep on potassium phosphate buffer(0.05M,pH7.8,con- the reaction are given in Fig.1.As reported by taining 0.1mM EDTA)was used in each stain- Arneson9),the chemiluminescence of the xanthine less steel dish and 0.05ml of 5U/ml xanthine ox- oxidase/acetaldehyde system first increased and idase and a small volume (0.05-0.25ml) of rea- then decreased. Dilazep inhibited the chemilu- gents were added.Each dish was incubated in- minescence dose-dependently.The IC50(the side the counting chamber and background concentration of each drug required to inhibit counts were read for 3 min before initiation of the chemiluminescence by 50%)of dilazep is2.9 the chemiluminescence reaction. The reaction 10-5 M(Fig.2).Catalase,SOD,allopurinol •~ Jpn J Clin Chem Vol.19,No.4,Dec.,1990.351 Fig.3.Inhibition of chemilumineseene einaxanth- Fig.4.Effeet of dilazep(○)and allopurinol(●)on. ine oxidase/aeetaldehyde system by1O2quen- xanthine oxidase activity chers and・OH seavengers Xanthine oxidase(3mU)was preincubated at Conditions are as in Fig.1. 37℃with dilazep or allopurinol in 0.9ml of Tris buffer(0.078M,pH8.0).The reaction and DMSO10),a hydroxyl radical scavenger,also was started by adding 0.1ml of 10mM xanth- ine solution.Thirty minutes after the begin- inhibited the chemiluminescence dose-depen- ning,1ml of 10%PCA was added in the reac- dently(Fig.2),and the IC50 values are 1.7× tion mixture and the formation of uricacid 10-9M,3.5×10-9M,3.8×10-6 M and 3.0× was measured. 10-3M,respectively.As shown in Fig.3,DAB- CO(10-2M),a quencher of 1O211),inhibited the chemiluminescence by87%.Other quenchers of The chemiluminescence from the xanthine lO 211),histidine(His,10-2M)and sodium azide oxidase system has been attributed to the pro- (10-2M),inhibited the chemiluminescence by duction of1O2 by the interaction of O2- with 97%and62%,respectively.Mannitol(Man,0.1 H2O29).On the other hand,Nagano and M),methionine(Met,10-2M),benzoic acid Fridovichll) reported that there is no detectable (Benz,10-2M)and ethanol(EtOH,0.24M),which production of1O2by the xanthine oxidase reac- are known ･OH ScavengerS10,11),inhibited the Che- tion.Thus,we investigated the effect of 1O2 miluminescence by74%,99%,76%and52%,re- quenchers (DABCO,histidine and azide) on the spectively. chemiluminescence from the xanthine oxidase Fig.4 shows the effects of allopurinol and reaction.The results show that these1O2quen- dilazep on xanthine oxidase activity.Allopurinol chers inhibit chemiluminescence.We also deter- directly inhibited xanthine oxidase(IC50 value mined that SOD,catalase and •EHO scavengers is5•~10-6M),whereas dilazep had no signifi- (DMSO, mannitol,methionine,benzoic acid and cant effect.The IC50 of allopurinol on xanthine ethanol) inhibit chemiluminescence.These re- oxidase activity was about the same as on che- sults suggest that not only O2-,H2O2 and •EOH miluminescence. but also 1O2 is responsible for the chemilu- minescence.Dilazep inhibited the chemilu- Discussion minescence in such a system,whereas it has no significant effect on the xanthine oxidase reac- We did not use xanthine,but instead acetal- tion,indicating that dilazep exhibits a scaven- dehyde,as the substrate in the xanthine oxidase ger-like function.Further work is necessary to system,because the luminescense yield for the identify the radical species scavenged by xanthine oxidase/acetaldehyde system was high- dilazep.Allopurinol inhibited both the chemilu- er than that of xanthine oxidase/xanthine sys- minescence and the oxidation of xanthine at the tem,and the reaction with acetaldehyde was same concentration.This indicates that allopuri- highly reproducible. nol inhibited the chemiluminescence through the 352 inhibition of xanthine oxidase and not through a 4) Hirai K and Koketsu K: Effect of comelian on radical scavenging effect. bullfrog sympathetic ganglion cells, Kurume- Dilazep is reported to be effective in pre- Igakkai-Zasshi, 43: 460-467, 1980 (in Japanese). 5) Yamamoto S, Nakajima K and Nagakura M: A venting re-circulation impairment6)and lipid possible mechanism of dilazep (Comelian) on en- peroxi dation7)after cerebral ischemia.The hancement of red cell deformability, Jan Pharma- mechanisms of these actions have not been clar- col Ther, 11: 4273-4277, 1983 (in Japanese). ified.Recently,oxygen free radicals have been 6) Kondo S, Kawada M and Sano N: Effects of suggested as mediators of ischemic brain dilazep on cerebral blood flow under normal con- damage8).Therefore,we tested the efficacy of ditions and recirculation impairment after cere- dilazep in scavenging free radicals in a xanthine bral ischemia, Folia Pharmacol Japon, 77: oxidase system. The results show that dilazep 205-211, 1981 (in Japanese). has a radical scavenging function and the IC50 7) Yamauchi Y, Ikuta J, Shimizu S and Nakamura M value is 2.9•~10-5M.This inhibition of dilazep : Effect of dilazep dihydrochloride on ischemia is stronger than that of other radical scavengers and reperfusion-indused cerebral injury in spon- taneously hypertensive rats, Folia Pharmacol and quenchers used in this study.In addition, Japon, 95: 239-246, 1990 (in Japanese). Yonemitsu,et al12)reported that dilazep has a 8) Demopoulos HB, Flamm ES, Seligman ML, high affinity for blood vessels,and Tamaki,et Jorgensen E and Ransohoff J: Antioxidant effects al13)showed that dilazep protects endothelial of barbiturates in model membranes undergoing cells from hydroperoxide-induced injury in vitro. free radical damage, Acta Neurol Scand, 56: These lines of evidence suggest that the free Suppl. 64, 152-153, 1977. radical scavenging activity of dilazep may playa 9) Arneson RM: Substrate-induced chemiluminesc- role in its brain protective action. ence of xanthine oxidase and aldehyde oxidase, Arch Biochem Biophys, 136: 352-360, 1970. References 10) Nakagami K, Shingu M and Nobunaga M: Oxygen radical-induced endothelial cell damage, The 1) Sano N, Katsuki S and Kawada M: Enhancement Saishin-Igaku, 39 : 1334-1341, 1984(in Japan- of coronary vasodilator action of adenosine by ese). 1,4-bis [3-(3,4,5-trimethoxybenzoyloxy)-propyl]- 11) Nagano T and Fridovich I: Does the aerobic perhydro-1, 4-diazepine (Dilazep I.N.N), Arznei- mittelforschung, 22:1655-1657, 1972. xanthine oxidase reaction generate singlet ox- 2) Yoshinaka Y and Uchida Y: Inhibition of ygen? Photochem Photobiol, 41: 33-37, 1985.
Load more

Recommended publications
  • SYNTHESIS and BIOLOGICAL Actnnry of CONFORMATIONALLY CONSTRAINED WLEOSIDES and NUCLEOTIDES
    SYNTHESIS AND BIOLOGICAL ACTnnrY OF CONFORMATIONALLY CONSTRAINED WLEOSIDES AND NUCLEOTIDES A thesis submitted in conformity with the requirements for the degree of Masters of Science Graduate Department of Chemistry University of Toronto National Library Bibliothèque nationaie B*m ofCanada du Canada Acquisitions and Acquisitions et Bibliographie Setvices services bibliographiques 395 Wellington Street 395. rue Wellington ûttawaON K1AW OctawaON KlAW canada canada The author has granted a non- L'auteur a accorde une licence non exclusive Licence allowing the exclusive permettant à la National Library of Canada to Bibliothèque nationale du Canada de reproduce, loan, distribute or sell reproduire, prêter, distn'buer ou copies of this thesis in microform, vendre des copies de cette thèse sous paper or electronic formats. la forme de microfiche/fïlm, de reproduction sur papier ou sur format électronique. The author retains ownership of the L'auteur conserve la propriété du copyright in this thesis. Neither the droit d'auteur qui protège cette thèse. thesis nor substantial extracts fiom it Ni la thèse ni des extraits substantiels may be printed or otherwise de celle-ci ne doivent être imprimés reproduced without the author's ou autrement reproduits sans son permission. autorisation. Spthesis and Biologicai Activity of Conformationaliy Constrained NucIeosides and Nuc1eotides Degree of Master of Science, 1998 by Girolamo Tusa Graduate Department of Chemistry, University of Toronto This thesis outhes the synthesis of a variety of confonnationally constrained nucleosides and nucleotide analogues. The conformationally 'locked" analogues closely resemble specific conformers of natural nucleosides and nucieotides and were used to probe the conformationai specificity of particular physiological processes in PC 12 ce&; nucleoside transport (NT) activity and Pt-purinoceptor response.
    [Show full text]
  • Chronotropic, Dromotropic and Inotropic Effects of Dilazep in the Intact Dog Heart and Isolated Atrial Preparation Shigetoshi CH
    Chronotropic, Dromotropic and Inotropic Effects of Dilazep in the Intact Dog Heart and Isolated Atrial Preparation Shigetoshi CHIBA, M.D., Miyoharu KOBAYASHI, M.D., Masahiro SHIMOTORI,M.D., Yasuyuki FURUKAWA, M.D., and Kimiaki SAEGUSA, M.D. SUMMARY When dilazep was administered intravenously to the anesthe- tized donor dog, mean systemic blood pressure was dose depend- ently decreased. At a dose of 0.1mg/Kg i.v., the mean blood pressure was not changed but a slight decrease in heart rate was usually observed in the donor dog. At the same time, a slight but significant decrease in atrial rate and developed tension of the iso- lated atrium was induced. Within a dose range of 0.3 to 1mg/Kg i.v., dilazep caused a dose related decrease in mean blood pressure, bradycardia in the donor dog, and negative chronotropic, dromo- tropic and inotropic effects in the isolated atrium. At larger doses of 3 and 10mg/Kg i.v., dilazep caused marked hypotension, fre- quently with severe sinus bradycardia or sinus arrest, especially in isolated atria. When dilazep was infused intraarterially at a rate of 0.2-1 ƒÊ g/min into the cannulated sinus node artery of the isolated atrium, negative chrono- and inotropic effects were dose dependently in- duced. With respect to dromotropism, SA conduction time (SACT) was prolonged at infusion rates of 0.2 and 0.4ƒÊg/min. But at 1ƒÊg, dilazep caused an increase or decrease of SACT, indicating a shift of the SA nodal pacemaker. It is concluded that dilazep has direct negative chrono-, dromo- and inotropic properties on the heart at doses which produced no significant hypotension.
    [Show full text]
  • Use of Uridine in Combination with Choline for the Treatment Of
    (19) TZZ ¥ _T (11) EP 2 329 829 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/7072 (2006.01) A61K 31/14 (2006.01) 16.04.2014 Bulletin 2014/16 A61K 31/685 (2006.01) A61P 25/28 (2006.01) (21) Application number: 10075661.8 (22) Date of filing: 30.07.1999 (54) Use of uridine in combination with choline for the treatment of neurological disorders Verwendung von Uridin in Kombination mit Cholin zur Behandlung neurologischer Erkrankungen Utilisation de l’uridine en combinaison avec la choline pour le traitement des maladies neurologiques (84) Designated Contracting States: • CACABELOSR ET AL: "THERAPEUTIC EFFECTS AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU OF CDP-CHOLINE IN ALZHEIMER’S DISEASE MC NL PT SE COGNITION, BRAIN MAPPING, CEREBROVASCULAR HEMODYNAMICS, AND (30) Priority: 31.07.1998 US 95002 P IMMUNE FACTORS", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, NEW YORK (43) Date of publication of application: ACADEMY OF SCIENCES, NEW YORK, NY, US, 1 08.06.2011 Bulletin 2011/23 January 1996 (1996-01-01), pages 399-403, XP008065562, ISSN: 0077-8923 (62) Document number(s) of the earlier application(s) in • SPIERS P A ET AL: "CITICOLINE IMPROVES accordance with Art. 76 EPC: VERBAL MEMORY IN AGING", ARCHIVES OF 09173495.4 / 2 145 627 NEUROLOGY, AMERICAN MEDICAL 07116909.8 / 1 870 103 ASSOCIATION, CHICAGO, IL, US, vol. 53, no. 5, 99937631.2 / 1 140 104 1 May 1996 (1996-05-01), pages 441-448, XP008028412, ISSN: 0003-9942 (73) Proprietor: Massachusetts Institute of Technology • WEISS G B: "Metabolism and actions of CDP- Cambridge, Massachusetts 02142-1601 (US) choline as an endogenous compound and administered exogenously as citicoline.", LIFE (72) Inventors: SCIENCES 1995 LNKD- PUBMED:7869846, vol.
    [Show full text]
  • Long-Term Oral Administration of Dipyridamole Improves Both
    913 Hypertens Res Vol.30 (2007) No.10 p.913-919 Original Article Long-Term Oral Administration of Dipyridamole Improves Both Cardiac and Physical Status in Patients with Mild to Moderate Chronic Heart Failure: A Prospective Open-Randomized Study Shoji SANADA1),2), Hiroshi ASANUMA3), Yukihiro KORETSUNE4), Kouki WATANABE5), Shinsuke NANTO6), Nobuhisa AWATA7), Noritake HOKI2), Masatake FUKUNAMI2), Masafumi KITAKAZE3), and Masatsugu HORI1) Adenosine is known as an endogenous cardioprotectant. We previously reported that plasma adenosine lev- els increase in patients with chronic heart failure (CHF), and that a treatment that further elevates plasma adenosine levels may improve the pathophysiology of CHF. Therefore, we performed a prospective, open- randomized clinical trial to determine whether or not exposure to dipyridamole for 1 year improves CHF pathophysiology compared with conventional treatments. The study enrolled 28 patients (mean±SEM: 66±4 years of age) attending specialized CHF outpatient clinics with New York Heart Association (NYHA) class II or III, no major complications, and stable CHF status during the most recent 6 months under fixed medica- tions. They were randomized into three groups with or without dipyridamole (Control: n=9; 75 mg/day: n=9; 300 mg/day: n=10) in addition to their original medications and were followed up for 1 year. The other drugs were not altered. Among the enrolled patients, 100%, 4%, 100%, and 79% received angiotensin-converting enzyme inhibitors, aldosterone analogue, loop diuretics, and β-adrenoceptor blocker, respectively. Fifteen patients suffered from dilated cardiomyopathy, and 7/3/3 patients suffered from ischemic/valvular/hyperten- sive heart diseases, respectively. Mean blood pressure was comparable among the groups.
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States (2019) Revision 13 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2019) Revision 13 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Mechanisms of Uptake and Resistance to Troxacitabine, a Novel Deoxycytidine Nucleoside Analogue, in Human Leukemic and Solid Tumor Cell Lines
    [CANCER RESEARCH 61, 7217–7224, October 1, 2001] Mechanisms of Uptake and Resistance to Troxacitabine, a Novel Deoxycytidine Nucleoside Analogue, in Human Leukemic and Solid Tumor Cell Lines Henriette Gourdeau,1,2 Marilyn L. Clarke,1 France Ouellet, Delores Mowles, Milada Selner, Annie Richard, Nola Lee, John R. Mackey, James D. Young,3 Jacques Jolivet, Ronald G. Lafrenie`re, and Carol E. Cass4 Shire BioChem Inc., Laval, Que´bec, H7V 4A7 Canada [H. G., F. O., A. R., N. L., J. J., R. G. L.]; Departments of Oncology [M. L. C., J. R. M., C. E. C.] and Physiology [J. D. Y.], University of Alberta, Alberta T6G 1Z2 Canada; and Cross Cancer Institute, Edmonton, Alberta T6G 1Z2 Canada [M. L. C., D. M., M. S., J. R. M., C. E. C.] ABSTRACT oxycytidine analogues such as gemcitabine (2Ј,2Ј-difluorodeoxycyti- dine; dFdC) and cytarabine (1-␤-D-arabinofuranosylcytosine; araC), -Troxacitabine (Troxatyl; BCH-4556; (-)-2؅-deoxy-3؅-oxacytidine), a de which are in the ␤-D configuration, troxacitabine has a nonnatural ␤-L oxycytidine analogue with an unusual dioxolane structure and nonnatural configuration. Troxacitabine, which shares the same intracellular ac- L-configuration, has potent antitumor activity in animal models and is in clinical trials against human malignancies. The current work was under- tivation pathway as gemcitabine and cytarabine, undergoes a series of taken to identify potential biochemical mechanisms of resistance to trox- phosphorylation reactions through a first rate-limiting step catalyzed 5 acitabine and to determine whether there are differences in resistance by dCK (EC 2.7.1.74) to form the active triphosphate nucleotide.
    [Show full text]
  • Jp Xvii the Japanese Pharmacopoeia
    JP XVII THE JAPANESE PHARMACOPOEIA SEVENTEENTH EDITION Official from April 1, 2016 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the convenience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 64 Pursuant to Paragraph 1, Article 41 of the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices (Law No. 145, 1960), the Japanese Pharmacopoeia (Ministerial Notification No. 65, 2011), which has been established as follows*, shall be applied on April 1, 2016. However, in the case of drugs which are listed in the Pharmacopoeia (hereinafter referred to as ``previ- ous Pharmacopoeia'') [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as ``new Pharmacopoeia'')] and have been approved as of April 1, 2016 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as of March 31, 2016 as those exempted from marketing approval pursuant to Paragraph 1, Article 14 of the Same Law (hereinafter referred to as ``drugs exempted from approval'')], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on September 30, 2017.
    [Show full text]
  • Brian F King and Andrea Townsend- Nicholson University College
    BrianFKingandAndreaTownsend- P2XReceptors Nicholson P2Xreceptors(P2XRs)areligand-gatedion-channels (LGICs)widelydistributedamongstvarioustissue UniversityCollegeLondon,GowerStreet, types,includingautonomic,central,entericand London,WC1E6BT,UK. sensoryneurons,cochlearandretinalcells, endotheliumandepithelium,vascularandvisceral BrianKingisaSeniorLecturerinthe smoothmuscle,heartanddevelopingskeletal DepartmentofPhysiology,andAndrea muscle,bone,haemopoieticcells.TheseLGICsserve Townsend-NicholsonaLecturerinthe tocontroltheexcitabilityoftheirhostcellsthrough DepartmentofBiochemistryandMolecular twoprocesses:i)influxofextracellularsodiumionsto elicitdepolarisation,andii)influxofextracellular Biology.Theyshareacommoninterestin calciumionstoactivateinternalenzymes. purinesignallingatrecombinantandnative P1andP2receptorsandhaveworked P2XRassembly togetheroverthelastsevenyearsonthe Sevenbuildingblocks, orsubunitproteins,are isolationandcharacterisationofnucleotide involvedintheconstructionofP2XRs.Theseseven receptors. buildingblocks–theP2X17toP2Xsubunits–have beenclonedfromhumanandratcDNAlibrariesand, insomecases,alsofrommouse,guinea-pig,chick andzebrafishlibraries.1,2 Fewstructuraldifferences havebeennotedbetweenspeciesorthologuesofthe Introduction sameP2Xsubunit.However,thedegreeofhomology canbeaslittleas27%betweendifferentsubunitsof Extracellularnucleotidesignallingmolecules,suchas thesamespecies.1 Furthermore,theP2Xgenesare ATP,ADP,UTPandUDP,workthroughspecific complexand,duringtranscription,canundergo ionotropic(P2X)ormetabotropic(P2Y)cell-surface
    [Show full text]
  • Effect of Oren-Gedoku-To on Platelet Aggregation
    Acta Medica et Biologica Vol. 39, No.4, 153-159 1991 Effect of Oren-gedoku-to on Platelet Aggregation Ken-ichi WATANABE Yasushi MIYAKITA Takayuki INOMATA Masataka SUZUKI Minoru TAKAHASHI Sen KOYAMA Kaoru SUZUKI Fumiaki MASANI and Akira SHIBATA IDivision of Cardiology, Tsubame Rosai Hospital Sawatari 633, Tsubame City Niigata 959-12 and 2Department of Internal Medicine I, Niigata University School of Medicine Received April 5, 1991 Summary. A traditional Chinese herbal medicine hypertension in 8 patients, and myocardial infarction "Oren-gedoku-to" (~Jlf9irll~) was administered to 21 in 4 patients. The population consisted of 3 males and patients with cerebrovascular disease. In 17 cases (81 %) 18 females aged 45 to 82 (70 ± 8, mean± ISD) years. symptomatic improvement was observed. Abnormally At least six months had elapsed after the first TIA, increased platelet aggregation in three cases returned myocardial infarction, or cerebral infarction. No to normal levels after administration. Oren-gedoku-to platelet aggregation inhibitors nor anti-coagulant may be useful for patients with cerebrovascular disease who present vague complaints. drugs had been administered (particularly, ticlopidine, dipyridamole, trapidil, dilazep, cilostazol, halidor, or warfarin). Other medicines were given continually during the examination period. The prescriptions and INTRODUCTION dosages were maintained as consistently with the original as possible. Essential hypertension, diabetes mellitus and hyper­ A daily dosage of 5.0-7.5 grams of oren-gedoku-to lipidemia are known risk factors for myocardial was orally administered. Before and 14 days after the infarction and cerebral infarction. Increased platelet initial administration, the following examinations aggregation has more recently been recognized as were conducted early in the morning: another risk factor.
    [Show full text]
  • Cellular Uptake and Intracellular Phosphorylation of GS-441524: Implications for Its Effectiveness Against COVID-19
    viruses Review Cellular Uptake and Intracellular Phosphorylation of GS-441524: Implications for Its Effectiveness against COVID-19 Henrik Berg Rasmussen 1,2,*, Gesche Jürgens 3, Ragnar Thomsen 4 , Olivier Taboureau 5, Kornelius Zeth 2, Poul Erik Hansen 2 and Peter Riis Hansen 6 1 Institute of Biological Psychiatry, Mental Health Centre Sct. Hans, DK-4000 Roskilde, Denmark 2 Department of Science and Environment, Roskilde University Center, DK-4000 Roskilde, Denmark; [email protected] (K.Z.); [email protected] (P.E.H.) 3 Clinical Pharmacology Unit, Zealand University Hospital, DK-4000 Roskilde, Denmark; [email protected] 4 Section of Forensic Chemistry, Department of Forensic Medicine, Faculty of Health Sciences, University of Copenhagen, DK-2100 Copenhagen, Denmark; [email protected] 5 INSERM U1133, CNRS UMR 8251, Université de Paris, F-75013 Paris, France; [email protected] 6 Department of Cardiology, Herlev and Gentofte Hospital, DK-2900 Hellerup, Denmark; [email protected] * Correspondence: [email protected] Abstract: GS-441524 is an adenosine analog and the parent nucleoside of the prodrug remdesivir, which has received emergency approval for treatment of COVID-19. Recently, GS-441524 has been proposed to be effective in the treatment of COVID-19, perhaps even being superior to remdesivir for treatment of this disease. Evaluation of the clinical effectiveness of GS-441524 requires understanding Citation: Rasmussen, H.B.; Jürgens, of its uptake and intracellular conversion to GS-441524 triphosphate, the active antiviral substance. G.; Thomsen, R.; Taboureau, O.; Zeth, We here discuss the potential impact of these pharmacokinetic steps of GS-441524 on the formation K.; Hansen, P.E.; Hansen, P.R.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Use of Uridine in Combination with Choline for the Treatment of Memory
    (19) TZZ ¥ __T (11) EP 2 322 187 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/7072 (2006.01) A61K 31/14 (2006.01) 14.05.2014 Bulletin 2014/20 A61K 31/685 (2006.01) A61P 25/28 (2006.01) (21) Application number: 10075660.0 (22) Date of filing: 30.07.1999 (54) Use of uridine in combination with choline for the treatment of memory disorders Verwendung von Uridin in Kombination mit Cholin zur Behandlung von Gedächtnisstörungen Utilisation de l’uridine en combinaison avec la choline pour le traitement des maladies de la mémoire (84) Designated Contracting States: (56) References cited: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU WO-A-97/45127 CH-A5- 680 334 MC NL PT SE DE-A1- 2 508 474 DE-A1- 2 629 845 DE-U1- 9 412 374 US-A- 4 221 784 (30) Priority: 31.07.1998 US 95002 P US-A- 4 994 442 US-A- 5 567 689 US-A- 5 700 590 (43) Date of publication of application: 18.05.2011 Bulletin 2011/20 • CACABELOSR ET AL: "THERAPEUTIC EFFECTS OF CDP-CHOLINE IN ALZHEIMER’S DISEASE (62) Document number(s) of the earlier application(s) in COGNITION, BRAIN MAPPING, accordance with Art. 76 EPC: CEREBROVASCULAR HEMODYNAMICS, AND 09173495.4 / 2 145 627 IMMUNE FACTORS", ANNALS OF THE NEW 07116909.8 / 1 870 103 YORK ACADEMY OF SCIENCES, NEW YORK 99937631.2 / 1 140 104 ACADEMY OF SCIENCES, NEW YORK, NY, US, 1 January 1996 (1996-01-01), pages 399-403, (73) Proprietor: Massachusetts Institute of Technology XP008065562, ISSN: 0077-8923 Cambridge, Massachusetts 02142-1601 (US) • SPIERS P A ET AL: "CITICOLINE IMPROVES VERBAL MEMORY IN AGING", ARCHIVES OF (72) Inventors: NEUROLOGY, AMERICAN MEDICAL • Watkins, Carol ASSOCIATION, CHICAGO, IL, US, vol.
    [Show full text]